# Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

> **NCT04140526** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **OncoC4, Inc.** · enrollment: 733 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Advanced Solid Tumor
- Metastatic Melanoma
- Metastatic Head and Neck Carcinoma
- Metastatic Renal Cell Carcinoma
- Metastatic Colorectal Cancer
- Sarcomas
- Metastatic Prostate Cancer
- Ovarian Cancer
- Small Cell Lung Cancer
- Metastatic Breast Cancer
- Pancreas Cancer
- Gastric Cancer
- Esophageal Cancer
- Gastroesophageal Junction Adenocarcinoma
- Cervical Cancer
- Adenoid Cystic Carcinoma
- Salivary Gland Cancer
- Urothelial Carcinoma

## Interventions

- **DRUG:** ONC-392
- **DRUG:** Pembrolizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04140526
- **Lead sponsor:** OncoC4, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-16
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 733 (ESTIMATED)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04140526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04140526, "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04140526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*